Safety of PD-1 inhibitor in preoperative treatment of liver transplantation for liver cancer
-
摘要:
目的 探讨程序性细胞死亡蛋白1（PD-1）抑制剂用于原发性肝癌（肝癌）肝移植术前治疗的安全性。 方法 回顾性分析7例术前应用PD-1抑制剂的肝癌肝移植受者的临床资料，总结受者免疫相关不良反应（irAE）发生情况及预后情况，评估PD-1抑制剂在肝癌肝移植受者中使用的安全性。 结果 7例肝癌肝移植受者术前使用PD-1抑制剂，使用疗程为1~20个，自停药至手术间隔时间为6~120 d。5例受者发生不同程度的irAE，其中疲乏3例、发热2例、脱发2例、皮疹2例、腹泻1例、恶心1例、心肌炎1例，多数irAE毒性分级为G1~2级，1例发生G5级毒性反应（致死性心肌炎），并导致受者死亡。1例受者于术后7 d发生排斥反应，经糖皮质激素冲击治疗及增加他克莫司剂量后好转。 结论 PD-1抑制剂可用于肝癌肝移植术前治疗，但应密切注意其irAE及术后排斥反应的发生。 Abstract:Objective To evaluate the safety of programmed cell death protein 1 (PD-1) inhibitor in the treatment of primary liver cancer (liver cancer) before liver transplantation. Methods Clinical data of 7 recipients given with PD-1 inhibitor before liver transplantation for liver cancer were retrospectively analyzed. The incidence of immune-related adverse event (irAE) and clinical prognosis of the recipients were summarized. The safety of PD-1 inhibitor in recipients prior to liver transplantation for liver cancer was evaluated. Results Seven recipients were treated with PD-1 inhibitor with 1-20 courses before liver transplantation for liver cancer. The time interval from drug withdrawal to liver transplantation was 6-120 d. Five recipients suffered from irAE of different degrees, including fatigue in 3 cases, fever in 2 cases, alopecia in 2 cases, rash in 1 case, nausea in 1 case and myocarditis in 1 case, respectively. A majority of these irAE were classified as grade Ⅰ-Ⅱ. One recipient died from grade Ⅴ irAE (fatal myocarditis). One recipient developed rejection at postoperative 7 d, which were mitigated after glucocorticoid pulse therapy combined with increased dosage of tacrolimus. Conclusions PD-1 inhibitor can be applied in preoperative treatment before liver transplantation for liver cancer. Nevertheless, the incidence of irAE and postoperative rejection should be intimately monitored. -
表 1 7例肝癌肝移植受者的临床资料
Table 1. Clinical data of 7 recipients after liver transplantation for liver cancer
例序 年龄（岁） PD-1抑制剂 药物剂量（mg） 使用疗程（个） 停药至手术间隔（d） 桥接/降期治疗 靶向治疗 术后免疫抑制方案 术后免疫诱导 不良反应 毒性分级 排斥反应 预后 1 60 帕博利珠单抗 100 5 12 TACE+肝癌切除+放疗 索拉非尼序贯仑伐替尼 三联 有 腹泻、皮疹、脱发、疲乏 G1~2级 无 存活 2 50 卡瑞利珠单抗 200 1 18 无 仑伐替尼 三联 有 发热 G1~2级 无 存活 3 49 信迪利单抗 100 4 120 TACE+肝癌切除 仑伐替尼 三联 无 脱发、恶心、疲乏 G1~2级 有 存活 4 56 信迪利单抗+纳武单抗 100 2 18 无 仑伐替尼 三联 无 发热、皮疹、疲乏 G1~2级 无 存活 5 56 纳武单抗 100 5 6 肝癌切除+TACE 仑伐替尼 三联 有 心肌炎 G5级 无 死亡 6 55 信迪利单抗 100 20 36 TACE 仑伐替尼 二联 有 无 无 无 存活 7 60 卡瑞利珠单抗 200 5 10 无 索拉非尼 二联 有 无 无 无 存活 
下载: 导出CSV
-
[1] 张笑晨, 胡玉琳. 晚期肝细胞癌患者PD-1阻断期间的疾病超进展[J]. 临床肝胆病杂志, 2020, 36(11): 2578. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202011053.htmZHANG XC, HU YL. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma[J]. J Clin Hepatol, 2020, 36(11): 2578. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202011053.htm [2] XU C, CHEN YP, DU XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network Meta-analysis[J]. BMJ, 2018, 363: k4226. DOI: 10.1136/bmj.k4226. [3] MUNKER S, DE TONI EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6(7): 970-973. DOI: 10.1177/2050640618774631. [4] KUMAR V, SHINAGARE AB, RENNKE HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature[J]. Oncologist, 2020, 25(6): 505-514. DOI: 10.1634/theoncologist.2019-0659. [5] 宾阳阳, 李杰群, 李强, 等. PD-1单克隆抗体治疗实体器官移植术后恶性肿瘤的系统评价[J]. 器官移植, 2020, 11(3): 384-390. DOI: 10.3969/j.issn.1674-7445.2020.03.011.BIN YY, LI JQ, LI Q, et al. Systematic evaluation on PD-1 monoclonal antibody in the treatment of malignant tumor after solid organ transplantation[J]. Organ Transplant, 2020, 11(3): 384-390. DOI: 10.3969/j.issn.1674-7445.2020.03.011. [6] SCHWACHA-EIPPER B, MINCIUNA I, BANZ V, et al. Immunotherapy as a downstaging therapy for liver transplantation[J]. Hepatology, 2020, 72(4): 1488-1490. DOI: 10.1002/hep.31234. [7] NORDNESS MF, HAMEL S, GODFREY CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20(3): 879-883. DOI: 10.1111/ajt.15617. [8] JOHNSON DB, CHANDRA S, SOSMAN JA. Immune checkpoint inhibitor toxicity in 2018[J]. JAMA, 2018, 320(16): 1702-1703. DOI: 10.1001/jama.2018.13995. [9] POSTOW MA, SIDLOW R, HELLMANN MD. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. DOI: 10.1056/NEJMra1703481. [10] RIELLA LV, WATANABE T, SAGE PT, et al. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts[J]. Am J Transplant, 2011, 11(4): 832-840. DOI: 10.1111/j.1600-6143.2011.03451.x. [11] TANAKA K, ALBIN MJ, YUAN X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection[J]. J Immunol, 2007, 179(8): 5204-5210. DOI: 10.4049/jimmunol.179.8.5204. [12] SHI XL, MANCHAM S, HANSEN BE, et al. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction[J]. J Hepatol, 2016, 64(6): 1274-1282. DOI: 10.1016/j.jhep.2016.02.034. [13] MORITA M, FUJINO M, JIANG G, et al. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft[J]. Am J Transplant, 2010, 10(1): 40-46. DOI: 10.1111/j.1600-6143.2009.02859.x. [14] RIELLA LV, PATERSON AM, SHARPE AH, et al. Role of the PD-1 pathway in the immune response[J]. Am J Transplant, 2012, 12(10): 2575-2587. DOI: 10.1111/j.1600-6143.2012.04224.x. [15] ONO Y, PEREZ-GUTIERREZ A, NAKAO T, et al. Graft-infiltrating PD-L1hi cross-dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance[J]. Hepatology, 2018, 67(4): 1499-1515. DOI: 10.1002/hep.29529. [16] RAMIREZ CB, MARINO IR. The role of basiliximab induction therapy in organ transplantation[J]. Expert Opin Biol Ther, 2007, 7(1): 137-148. DOI: 10.1517/14712598.7.1.137. [17] HAMMERS HJ, PLIMACK ER, INFANTE JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study[J]. J Clin Oncol, 2017, 35(34): 3851-3858. DOI: 10.1200/JCO.2016.72.1985. [18] ZHANG JC, CHEN WD, ALVAREZ JB, et al. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity[J]. Acta Pharmacol Sin, 2018, 39(11): 1693-1698. DOI: 10.1038/s41401-018-0062-2. [19] MOSLEHI JJ, SALEM JE, SOSMAN JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J]. Lancet, 2018, 391(10124): 933. DOI: 10.1016/S0140-6736(18)30533-6. [20] MAHMOOD SS, FRADLEY MG, COHEN JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors[J]. J Am Coll Cardiol, 2018, 71(16): 1755-1764. DOI: 10.1016/j.jacc.2018.02.037. [21] ESCUDIER M, CAUTELA J, MALISSEN N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity[J]. Circulation, 2017, 136(21): 2085-2087. DOI: 10.1161/CIRCULATIONAHA.117.030571. [22] HARDY T, YIN M, CHAVEZ JA, et al. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report[J]. Cardiovasc Pathol, 2020, 46: 107202. DOI: 10.1016/j.carpath.2020.107202. [23] WANG F, SUN X, QIN S, et al. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China[J]. Chin Clin Oncol, 2020, 9(2): 16. DOI: 10.21037/cco.2020.03.08. [24] BURLA J, BLUEMEL S, BIEDERMANN L, et al. Retrospective analysis of treatment and complications of immune checkpoint inhibitor-associated colitis: histological ulcerations as potential predictor for a steroid-refractory disease course[J]. Inflamm Intest Dis, 2020, 5(3): 109-116. DOI: 10.1159/000507579. [25] WANG DY, SALEM JE, COHEN JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and Meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728. DOI: 10.1001/jamaoncol.2018.3923. [26] SALEM JE, MANOUCHEHRI A, MOEY M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study[J]. Lancet Oncol, 2018, 19(12): 1579-1589. DOI: 10.1016/S1470-2045(18)30608-9. [27] WINER A, BODOR JN, BORGHAEI H. Identifying and managing the adverse effects of immune checkpoint blockade[J]. J Thorac Dis, 2018, 10(Suppl 3): S480-S489. DOI: 10.21037/jtd.2018.01.111. -
下载: 
点击查看大图
表(1)
计量
- 文章访问数: 490
- HTML全文浏览量: 422
- PDF下载量: 110
- 被引次数: 0
